先舊後新配股籌資 希瑪眼科(3309.HK)連跌4日累跌超20%
格隆匯1月17日丨延續近日下跌走勢,希瑪眼科(3309.HK)今日繼續走弱,盤中一度跌近9%至5.6港元,為連續第四日下跌,股價創2021年5月以來新低,4日累計跌幅一度超22%。希瑪眼科曾於13日公佈,控股股東林順潮夫婦配售9000萬股,並將認購公司7650萬股新股,即出售1350萬舊股,套現8748萬港元,持股將降至55.4%。每股配售價6.48港元,較12日收盤價7.18港元折讓9.75%。公司集資4.96億港元,淨額4.91億港元,擬用於併購的資金、擴大集團的醫院和服務網絡,及擴充集團的一般營運資金。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.